The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications (Review)

Wu, Lei; Yang, Lili

doi:10.3892/ol.2018.8215

Cited by 46 publications

(47 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies reported a poor recurrence and free survival rate associated with the higher expressions in OGS. Another recent study also identified similar results with us demonstrated that the higher expressions of HMGB1 related to cancer development, tumor progression, and metastasis of lymph nodes 33 . On the other hand, we observed reduced levels of HMGB1 in treatment groups revealing that both the treatments successfully reduced the over expressions.…”

Section: Signaling Proteins Expression In Ogssupporting

confidence: 84%

Proteomic profiling and identification of significant markers from high-grade osteosarcoma after cryotherapy and irradiation

Madda

Chen

Wang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Biological reconstruction of allografts and recycled autografts have been widely implemented in highgrade osteogenic sarcoma. For treating tumor-bearing autografts, extracorporeal irradiation (ECIR) and liquid nitrogen (LN) freezing techniques are being used worldwide as a gold standard treatment procedure. Both the methods aim to eradicate the tumor cells from the local recurrence and restore the limb function. Therefore, it is essential and crucial to find, and compare the alterations at molecular and physiological levels of the treated and untreated OGS recycled autografts to obtain valuable clinical information for better clinical practice. Thus, we aimed to investigate the significantly expressed altered proteins from ECIR-and cryotherapy/freezing-treated OGS (n = 12) were compared to untreated OGS (n = 12) samples using LC-ESI-MS/MS analysis, and the selected proteins from this protein panel were verified using immunoblot analysis. From our comparative proteomic analysis identified a total of 131 differentially expressed proteins (DEPs) from OGS. Among these, 91 proteins were up-regulated (2.5 to 3.5-folds), and 40 proteins were down-regulated (0.2 to 0.5 folds) (p < 0.01 and 0.05). The functional enrichment analysis revealed that the identified DEPs have belonged to more than 10 different protein categories include cytoskeletal, extracellular matrix, immune, enzyme modulators, and cell signaling molecules. Among these, we have confirmed two potential candidates' expressions levels such as Fibronectin and Protein S100 A4 using western blot analysis. Our proteomic study revealed that LN-freezing and ECIR treatments are effectively eradicating tumor cells, and reducing the higher expressions of DEPs at molecular levels which may help in restoring the limb functions of OGS autografts effectively. To the best of our knowledge, this is the first proteomic study that compared proteomic profiles among freezing, ECIR treated with untreated OGS in recycled autografts. Moreover, the verified proteins could be used as prognostic or diagnostic markers that reveal valuable scientific information which may open various therapeutic avenues in clinical practice to improve patient outcomes.High-grade osteogenic sarcomas (OGS) are the most common primary malignant bone sarcomas that distress the bone and forms a matrix and osteoid around the knees 1-3 . It accounts one to three per million each year worldwide and has a high rate of incidence in children and adults 3,4 . Currently, the standard treatment procedures applicable for patients are neoadjuvant chemotherapy drugs combined with surgery, precision diagnostic instruments, and limb salvage operations 5 . At present, there are three reconstructive procedures available after resection of tumors that are affected with major joints, include tumor prosthesis, an osteoarticular allograft, and a composite biological reconstruction. Among these three options, biological reconstruction of allograft and autografts (recycled from the resected autogenic bone segment) technique has ...

show abstract

Section: Signaling Proteins Expression In Ogssupporting

confidence: 84%

Proteomic profiling and identification of significant markers from high-grade osteosarcoma after cryotherapy and irradiation

Madda

Chen

Wang

et al. 2020

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Earlier reports have revealed that downregulation of HMGB1 could lead to the inhibition of cell proliferation. Results clearly highlight our expectation that downregulation of HMGB1 could be directly related to the proliferation of cervical cancer cells [23]. It is worth noting that CD59-antibody conjugated formulation exhibited a significantly lower cell viability compared to that of free CDDP.…”

Section: Discussionsupporting

confidence: 65%

CD59 receptor targeted delivery of miRNA-1284 and Cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancers

Wang

Liang

2019

Preprint

View full text Add to dashboard Cite

Background: In this study, we have designed the CD59sp-conjugated miRNA-1284/cisplatin(CDDP)-loaded liposomes for the enhanced therapeutic effect against cervical cancers. Methods: A substantially higher uptake of CD59 antibody-conjugated miRNA-1284/CDDP-loaded liposomes (CD/LP-miCDDP) was attributed to the CD59-based receptor-mediated cellular internalization in HeLa cells. Results: MiR-1284 showed a typical concentration-dependent cell killing effect in the cervical cancer cells owing to the downregulation of HMGB1. CD59-antibody conjugated formulation exhibited a significantly lower cell viability compared to that of free CDDP and non-targeted LP-miCDDP. The combination of miR-1284 and CDDP could result in a synergistic anticancer effect on the cervical cancer cells. The IC50 value of CDDP, LP-miCDDP and CD/LP-miCDDP was observed to be 12.4 µg/ml, 7.23 µg/ml and 3.12 µg/ml, respectively. CD/LP-miCDDP exhibited remarkable cell/nuclei rupturing and apoptotic bodies’ formation indicating a severe apoptosis effect in HeLa cancer cells. Flow cytometer analysis showed that CD/LP-miCDDP resulted in maximum apoptosis effect (~60%) compared to CDDP (~20%) or miR-1284 (~12%) treated cells indicating the superior anticancer effect in the cancer cells. Conclusions: Finally, CD/LP-miCDDP significantly prolonged the blood circulation of encapsulated drug in rats with significantly higher AUC (o-t) , t 1/2 and lower CL compared to that of free CDDP. Overall, CD/LP-miCDDP could hold a promising potential in the treatment of cervical cancers.

show abstract

“…HMGB1 was identified as a direct downstream target gene of miR‐505 using bioinformatics method and it was further confirmed by the luciferase reporter assay. HMGB1 was overexpressed in RCC, and it also exhibited significantly elevated expression in renal cancer tissues that was closely related to the clinical prognosis of RCC patients (Wu & Yang, ; Yan, Ying, & Cai, ). In addition, previous studies have already showed that knock‐down of HMGB1 in RCC cell lines in vitro led to reduced growth in the tumor microenvironment, which provided a novel theoretical basis for preventing RCC using HMGB1 as the target (J. Li et al, ; Wu et al, ).…”

Section: Discussionmentioning

confidence: 99%

microRNA‐505 negatively regulates HMGB1 to suppress cell proliferation in renal cell carcinoma

Zhong

Qin

Zhou³

et al. 2019

Journal Cellular Physiology

View full text Add to dashboard Cite

microRNAs have been recognized to regulate a wide range of biology of renal cell carcinoma (RCC). Although miR‐505 has been reported to play as a suppressor in several human tumors, the physiological function of miR‐505 in RCC still remain unknown. Therefore, the role of miR‐505 and relevant regulatory mechanisms were investigated in RCC in this study. Quantitative real‐time polymerase chain reaction was conducted to detect the expression of miR‐505 and high mobility group box 1 (HMGB1) in both RCC tissues and cell lines. Immunohistochemical staining was used to assess the correlation between HMGB1 expression and PCNA expression in RCC tissues. Subsequently, the effects of miR‐505 on proliferation were determined in vitro using cell counting kit‐8 proliferation assays and 5‐ethynyl‐2′‐deoxyuridine incorporation. The molecular mechanism underlying the relevance between miR‐505 and HMGB1 was confirmed by luciferase assay. Xenograft tumor formation was used to reflect the proliferative capacity of miR‐505 in vivo experiments. Overall, a relatively lower miR‐505 and higher HMGB1 expression in RCC specimens and cell lines were found. HMGB1 was verified as a direct target of miR‐505 by luciferase assay. In vitro, overexpression of miR‐505 negatively regulates HMGB1 to suppress the proliferation in Caki‐1; meanwhile, knock‐down of miR‐505 negatively regulates HMGB1 to promote the proliferation in 769P. In addition, in vivo overexpression of miR‐505 could inhibit tumor cell proliferation in RCC by xenograft tumor formation. Therefore, miR‐505, as a tumor suppressor, negatively regulated HMGB1 to suppress the proliferation in RCC, and might serve as a novel therapeutic target for RCC clinical treatment.

show abstract

The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications (Review)

Cited by 46 publications

References 90 publications

Proteomic profiling and identification of significant markers from high-grade osteosarcoma after cryotherapy and irradiation

Proteomic profiling and identification of significant markers from high-grade osteosarcoma after cryotherapy and irradiation

CD59 receptor targeted delivery of miRNA-1284 and Cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancers

microRNA‐505 negatively regulates HMGB1 to suppress cell proliferation in renal cell carcinoma

Contact Info

Product

Resources

About